At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
A/California/07/09 live monovalent H1N1 vaccinebiological
Likely dose
A/California/07/09 live monovalent H1N1 vaccine 0.1mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults
In Brief
A Phase 4 clinical trial evaluating A/California/07/09 live monovalent H1N1 vaccine for Influenza. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedDec 2009
Primary CompletionApr 2010
Study CompletionJul 2010
TodayJul 2026
First PostedDec 2, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.6 years ago
Interventions
A/California/07/09 live monovalent H1N1 vaccinebiological
0.1mL per nares intranasally, second identical dose given 28 days after first vaccine